Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Interest & Investment Income (2021 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Interest & Investment Income for 8 consecutive years, with $206387.0 as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 46.05% to $206387.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $909747.0, a 64.45% decrease, with the full-year FY2025 number at $1.4 million, down 58.35% from a year prior.
  • Interest & Investment Income was $206387.0 for Q4 2025 at PharmaCyte Biotech, down from $217793.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $894181.0 in Q4 2023 to a low of $25619.0 in Q4 2021.
  • A 5-year average of $431394.4 and a median of $382562.0 in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: soared 1614.24% in 2022, then crashed 71.0% in 2025.
  • PharmaCyte Biotech's Interest & Investment Income stood at $25619.0 in 2021, then skyrocketed by 1614.24% to $439171.0 in 2022, then soared by 103.61% to $894181.0 in 2023, then tumbled by 57.22% to $382562.0 in 2024, then plummeted by 46.05% to $206387.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Interest & Investment Income are $206387.0 (Q4 2025), $217793.0 (Q3 2025), and $229875.0 (Q2 2025).